在因缺血性心力衰竭而引起的心脏衰竭中使用布辛多洛尔的β阻塞与异常性扩张性心肌病相比
S L Woodley1, E M Gilbert, J L Anderson
1Heart Failure Treatment Program, University of Utah School of Medicine, Salt Lake City.
Circulation
|December 1, 1991
概括
布辛多洛尔在心力衰竭患者中改善了心脏功能,特别是那些患有异常扩张心肌病的人. 缺血扩张性心肌病患者的改善较小,这表明对β阻塞的反应不同.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 研究了布辛多洛尔,一种具有血管扩张性质的非选择性β-阻断剂.
- 专注于因缺血性 (ISCDC) 和异常性 (IDC) 扩张性心肌病症引起的充血性心力衰竭患者.
研究的目的:
- 评估布辛多洛尔在ISCDC和IDC患者中的疗效.
- 为了比较ISCDC和IDC亚组之间的治疗反应.
主要方法:
- 双盲,安慰剂对照试验超过12周.
- 随机选择的患者按心力衰竭病因分层 (ISCDC与IDC).
- 在基线和研究结束时使用侵入性和非侵入性方法评估心力衰竭的严重程度.
主要成果:
- 布辛多洛尔显著改善了射出分数,左心室大小,填充压力,中风工作指数,并降低了整体队列中的诺阿基尼林水平.
- 改进主要是由IDC子集团推动的.
- 在ISCDC小组中,只有左心室大小显著改善.
结论:
- 用布辛多洛尔的β阻塞会根据心肌疾病的潜在原因引起数量上不同的反应.
- 治疗效果在缺血性心肌病和异常性扩张性心肌病之间有所不同.
相关概念视频
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


